Skip to main content

Articles

Page 29 of 36

  1. In Alzheimer’s disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeu...

    Authors: Mikko Hölttä, Robert A. Dean, Eric Siemers, Kwasi G. Mawuenyega, Wendy Sigurdson, Patrick C. May, David M. Holtzman, Erik Portelius, Henrik Zetterberg, Randall J. Bateman, Kaj Blennow and Johan Gobom
    Citation: Alzheimer's Research & Therapy 2016 8:11
    Content type: Research Published on:

  2. In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer’s disease (AD) after inf...

    Authors: Marielle Delnomdedieu, Sridhar Duvvuri, David Jianjun Li, Nazem Atassi, Ming Lu, H. Robert Brashear, Enchi Liu, Seth Ness and James W. Kupiec
    Citation: Alzheimer's Research & Therapy 2016 8:12
    Content type: Research Published on:

  3. Specific cutoff scores on the Mini Mental State Examination (MMSE) and the Logical Memory (LM) test are used to determine inclusion in Alzheimer’s disease (AD) clinical trials and diagnostic studies. These scr...

    Authors: Kimberly R. Chapman, Hanaan Bing-Canar, Michael L. Alosco, Eric G. Steinberg, Brett Martin, Christine Chaisson, Neil Kowall, Yorghos Tripodis and Robert A. Stern
    Citation: Alzheimer's Research & Therapy 2016 8:9
    Content type: Research Published on:

  4. There is an increasing interest in cognitive and functional outcomes in the respective stages of Alzheimer’s disease (AD) and in novel therapies particularly for the milder phases of AD. Our aim was to describ...

    Authors: Carina Wattmo, Lennart Minthon and Åsa K. Wallin
    Citation: Alzheimer's Research & Therapy 2016 8:7
    Content type: Research Published on:

  5. Development of new treatments for Alzheimer’s disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer’s Dise...

    Authors: Jana Podhorna, Tillmann Krahnke, Michael Shear and John E Harrison
    Citation: Alzheimer's Research & Therapy 2016 8:8
    Content type: Research Published on:

  6. This study was to investigate whether the previously proposed link between Alzheimer’s disease (AD) and decreased retinal nerve fiber layer thickness could be explained by the relationship between abnormal CSF...

    Authors: Eun Ji Lee, Tae-Woo Kim, Dae Seung Lee, Hyunjoong Kim, Young Ho Park, Jungeun Kim, Joon Woo Lee and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2016 8:6
    Content type: Research Published on:

  7. We assessed the impact of retinoid X receptor (RXR) agonist bexarotene on brain amyloid measured by amyloid imaging in patients with Alzheimer’s disease (AD) in a proof-of-concept trial.

    Authors: Jeffrey L. Cummings, Kate Zhong, Jefferson W. Kinney, Chelcie Heaney, Joanne Moll-Tudla, Abhinay Joshi, Michael Pontecorvo, Michael Devous, Anne Tang and James Bena
    Citation: Alzheimer's Research & Therapy 2016 8:4
    Content type: Research Published on:

  8. Alzheimer’s disease is the most frequent age-related dementia, and is currently without treatment. To identify possible targets for early therapeutic intervention we focused on glutamate excitotoxicity, a majo...

    Authors: Abdel G. Elkahloun, Roman Hafko and Juan M. Saavedra
    Citation: Alzheimer's Research & Therapy 2016 8:5
    Content type: Research Published on:

  9. Anxiety in dementia is common but not well studied. We studied the associations of anxiety longitudinally in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB).

    Authors: Monica H. Breitve, Minna J. Hynninen, Kolbjørn Brønnick, Luiza J. Chwiszczuk, Bjørn H. Auestad, Dag Aarsland and Arvid Rongve
    Citation: Alzheimer's Research & Therapy 2016 8:3
    Content type: Research Published on:

  11. Semiquantitative methods such as the standardized uptake value ratio (SUVR) require normalization of the radiotracer activity to a reference tissue to monitor changes in the accumulation of amyloid-β (Aβ) plaq...

    Authors: Sepideh Shokouhi, John W. Mckay, Suzanne L. Baker, Hakmook Kang, Aaron B. Brill, Harry E. Gwirtsman, William R. Riddle, Daniel O. Claassen and Baxter P. Rogers
    Citation: Alzheimer's Research & Therapy 2016 8:2
    Content type: Research Published on:

  12. Electroencephalography (EEG) microstates and brain network are altered in patients with Alzheimer’s disease (AD) and discussed as potential biomarkers for AD. Microstates correspond to defined states of brain ...

    Authors: Florian Hatz, Martin Hardmeier, Nina Benz, Michael Ehrensperger, Ute Gschwandtner, Stephan Rüegg, Christian Schindler, Andreas U. Monsch and Peter Fuhr
    Citation: Alzheimer's Research & Therapy 2015 7:78
    Content type: Research Published on:

  13. The increase in electroencephalogram (EEG) alpha3/alpha2 frequency power ratio has been demonstrated as a biomarker characteristic of subjects with mild cognitive impairment (MCI) who will develop Alzheimer’s ...

    Authors: D. V. Moretti
    Citation: Alzheimer's Research & Therapy 2015 7:80
    Content type: Research Published on:

  14. Studies have shown that proton pump inhibitors (PPIs) increase the brain burden of amyloid-beta (Aβ) and also create vitamin B12 deficiency. However, these two phenomena have deleterious effect on cognition and A...

    Authors: Sanjida Akter, Md. Rajib Hassan, Mohammad Shahriar, Nahia Akter, Md. Golam Abbas and Mohiuddin Ahmed Bhuiyan
    Citation: Alzheimer's Research & Therapy 2015 7:79
    Content type: Research Published on:

  15. Neuroinflammation and synaptic degeneration are major neuropathological hallmarks in Alzheimer’s disease (AD). Neurogranin and YKL-40 in cerebrospinal fluid (CSF) are newly discovered markers indicating synapt...

    Authors: Konstantin Hellwig, Hlin Kvartsberg, Erik Portelius, Ulf Andreasson, Timo Jan Oberstein, Piotr Lewczuk, Kaj Blennow, Johannes Kornhuber, Juan Manuel Maler, Henrik Zetterberg and Philipp Spitzer
    Citation: Alzheimer's Research & Therapy 2015 7:74
    Content type: Research Published on:

  16. Alzheimer’s disease brains are characterized by extracellular plaques containing the aggregated amyloid β42 (Aβ42) peptide and intraneuronal tangles containing hyperphosphorylated tau. Aβ42 is produced by sequent...

    Authors: Simon Sjödin, Kerstin K. A. Andersson, Marc Mercken, Henrik Zetterberg, Herman Borghys, Kaj Blennow and Erik Portelius
    Citation: Alzheimer's Research & Therapy 2015 7:77
    Content type: Research Published on:

  17. In this study of preclinical Alzheimer’s disease (AD) we assessed the added diagnostic value of using cerebrospinal fluid (CSF) Aβ ratios rather than Aβ42 in isolation for detecting individuals who are positiv...

    Authors: Katarzyna Adamczuk, Jolien Schaeverbeke, Hugo M. J. Vanderstichele, Johan Lilja, Natalie Nelissen, Koen Van Laere, Patrick Dupont, Kelly Hilven, Koen Poesen and Rik Vandenberghe
    Citation: Alzheimer's Research & Therapy 2015 7:75
    Content type: Research Published on:

  18. Radioligand imaging is a powerful in vivo method to assess the molecular basis of Alzheimer’s Disease. We therefore aimed to visualize the pathological deposition of fibrillar amyloid-β and neuronal dysfunction i...

    Authors: Ann-Marie Waldron, Cindy Wintmolders, Astrid Bottelbergs, Jonathan B. Kelley, Mark E. Schmidt, Sigrid Stroobants, Xavier Langlois and Steven Staelens
    Citation: Alzheimer's Research & Therapy 2015 7:76
    Content type: Research Published on:

  19. A recent study found a significant increase of ABCA7 loss-of-function variants in Alzheimer’s disease (AD) cases compared to controls. Some variants were located on noncoding regions, but it was demonstrated that...

    Authors: Jorge L. Del-Aguila, Maria Victoria Fernández, Jessica Jimenez, Kathleen Black, Shengmei Ma, Yuetiva Deming, David Carrell, Ben Saef, Bill Howells, John Budde and Carlos Cruchaga
    Citation: Alzheimer's Research & Therapy 2015 7:73
    Content type: Research Published on:

  20. This study aimed to investigate the feasibility of predicting the long–term effects of cholinesterase inhibitors (ChEI) with common clinical neuroimaging parameters of Alzheimer’s disease, including medial tem...

    Authors: Yu-Wen Cheng, Ta-Fu Chen, Ting-Wen Cheng, Ya-Mei Lai, Mau-Sun Hua, Ya-Fang Chen and Ming-Jang Chiu
    Citation: Alzheimer's Research & Therapy 2015 7:72
    Content type: Research Published on:

  21. Cerebrospinal fluid (CSF) biomarkers, although of established utility in the diagnostic evaluation of Alzheimer’s disease (AD), are known to be sensitive to variation based on pre-analytical sample processing....

    Authors: Alan Rembach, Lisbeth A. Evered, Qiao-Xin Li, Tabitha Nash, Lesley Vidaurre, Christopher J. Fowler, Kelly K. Pertile, Rebecca L. Rumble, Brett O. Trounson, Sarah Maher, Francis Mooney, Maree Farrow, Kevin Taddei, Stephanie Rainey-Smith, Simon M. Laws, S. Lance Macaulay…
    Citation: Alzheimer's Research & Therapy 2015 7:71
    Content type: Research Published on:

  22. Alzheimer’s disease is a debilitating condition, and the search for an effective treatment is ongoing. Inflammation, in reaction to amyloid deposition, is thought to accelerate cognitive decline. With tumor ne...

    Authors: Megan E. Roerink, Rob JM Groen, Gerben Franssen, Bianca Lemmers-van de Weem, Otto C. Boerman and Jos WM van der Meer
    Citation: Alzheimer's Research & Therapy 2015 7:70
    Content type: Research Published on:

  23. The potential effects of amalgam fillings on the development of Alzheimer’s disease (AD) are not well understood. The aim of the study was to evaluate the association between dental amalgam fillings and Alzhei...

    Authors: Yi-Hua Sun, Oswald Ndi Nfor, Jing-Yang Huang and Yung-Po Liaw
    Citation: Alzheimer's Research & Therapy 2015 7:65
    Content type: Research Published on:

  24. As currently used, the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) has low sensitivity for measuring Alzheimer’s disease progression in clinical trials. A major reason behind the low sen...

    Authors: Nishant Verma, S. Natasha Beretvas, Belen Pascual, Joseph C. Masdeu and Mia K. Markey
    Citation: Alzheimer's Research & Therapy 2015 7:64
    Content type: Research Published on:

  25. We compared the predictive ability of the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) to diagnose dementia in a community-based study.

    Authors: Jung-Lung Hsu, Yen-Chun Fan, Ya-Li Huang, Jui Wang, Wei-Hung Chen, Hou-Chang Chiu and Chyi-Huey Bai
    Citation: Alzheimer's Research & Therapy 2015 7:69
    Content type: Research Published on:

  26. The definition of “objective cognitive impairment” in current criteria for mild cognitive impairment (MCI) varies considerably between research groups and clinics. This study aims to compare different methods ...

    Authors: Brandy L. Callahan, Joel Ramirez, Courtney Berezuk, Simon Duchesne and Sandra E. Black
    Citation: Alzheimer's Research & Therapy 2015 7:68
    Content type: Research Published on:

  27. There have been recent reports about a decline in dementia incidence, but only little is known about trends in the mortality of patients with dementia. Only the simultaneous analysis of both trends can inform ...

    Authors: Gabriele Doblhammer, Anne Fink, Stephanie Zylla and Frans Willekens
    Citation: Alzheimer's Research & Therapy 2015 7:66
    Content type: Research Published on:

  29. Better characterization of the relationship between episodic memory and hippocampal volumes is crucial in early detection of neurodegenerative disease. We examined these relationships in a memory clinic popula...

    Authors: Aaron Bonner-Jackson, Shamseldeen Mahmoud, Justin Miller and Sarah J Banks
    Citation: Alzheimer's Research & Therapy 2015 7:61
    Content type: Research Published on:

  30. Chronic traumatic encephalopathy (CTE) is a progressive neurodegeneration associated with repetitive head impacts. Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) is a U01 project recently...

    Authors: Jesse Mez, Todd M. Solomon, Daniel H. Daneshvar, Lauren Murphy, Patrick T. Kiernan, Philip H. Montenigro, Joshua Kriegel, Bobak Abdolmohammadi, Brian Fry, Katharine J. Babcock, Jason W. Adams, Alexandra P. Bourlas, Zachary Papadopoulos, Lisa McHale, Brent M. Ardaugh, Brett R. Martin…
    Citation: Alzheimer's Research & Therapy 2015 7:62
    Content type: Research Published on:

  31. Inflammatory processes have previously been shown to influence cognition and progression of dementia. An involvement of interleukin (IL)-6 has in particular been suggested as altered levels of IL-6 in cerebros...

    Authors: Malin Wennström, Sara Hall, Katarina Nägga, Elisabet Londos, Lennart Minthon and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2015 7:63
    Content type: Research Published on:

  32. The Third National Alzheimer Plan (2008–2012) was a major public health initiative in France that included €200 million of funding for research in Alzheimer disease and related disorders (AD). The aim of this ...

    Authors: Nicole Haeffner-Cavaillon, Patrick Devos, Sylvie Ledoux and Joël Ménard
    Citation: Alzheimer's Research & Therapy 2015 7:60
    Content type: Research Published on:

  33. We examined the utility of cerebrospinal fluid (CSF) proteins, Chitinase-3-like protein 1 (CHI3L1 or YKL-40), a putative marker of inflammation, and Visinin-like protein-1 (VILIP-1), a marker for neuronal inju...

    Authors: Maartje I. Kester, Charlotte E. Teunissen, Courtney Sutphen, Elizabeth M. Herries, Jack H. Ladenson, Chengjie Xiong, Philip Scheltens, Wiesje M. van der Flier, John C. Morris, David M. Holtzman and Anne M. Fagan
    Citation: Alzheimer's Research & Therapy 2015 7:59
    Content type: Research Published on:

  34. Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than...

    Authors: Artur M N Coutinho, Fábio H G Porto, Fabio L S Duran, Silvana Prando, Carla R Ono, Esther A A F Feitosa, Lívia Spíndola, Maira O. de Oliveira, Patrícia H F do Vale, Helio R. Gomes, Ricardo Nitrini, Sonia M D Brucki and Carlos A. Buchpiguel
    Citation: Alzheimer's Research & Therapy 2015 7:58
    Content type: Research Published on:

  35. Alzheimer’s disease (AD) is associated with neurofibrillary pathology, including neurofibrillary tangles (NFT), neuritic plaques (NP) and neuropil threads containing aggregated microtubule associated protein t...

    Authors: Sally Hunter, Thais Minett, Tuomo Polvikoski, Elizabeta Mukaetova-Ladinska and Carol Brayne
    Citation: Alzheimer's Research & Therapy 2015 7:57
    Content type: Research Published on:

  36. Inflammatory responses in the brain, which can be demonstrated by changes in properties of microglia, the brain-resident macrophages, are a common feature of human neurodegenerative diseases. Different monocyt...

    Authors: Douglas G. Walker and Lih-Fen Lue
    Citation: Alzheimer's Research & Therapy 2015 7:56
    Content type: Review Published on:

  38. Aging occurs as a series of small steps, first causing cellular damage and then affecting tissues and organs. This is also true in the brain. Frailty, a state of increased risk due to accelerated deficit accum...

    Authors: Samuel D. Searle and Kenneth Rockwood
    Citation: Alzheimer's Research & Therapy 2015 7:54
    Content type: Review Published on:

  39. Amyloid-β (Aβ) has been investigated as a diagnostic biomarker and therapeutic drug target. Recent studies found that cerebrospinal fluid (CSF) Aβ fluctuates over time, including as a diurnal pattern, and incr...

    Authors: Brendan P. Lucey, Celedon Gonzales, Ujjwas Das, Jinhe Li, Eric R. Siemers, J. Randall Slemmon, Randall J. Bateman, Yafei Huang, Gerard B. Fox, Jurgen A.H.R. Claassen, Diane Slats, Marcel M. Verbeek, Gary Tong, Holly Soares, Mary J. Savage, Matthew Kennedy…
    Citation: Alzheimer's Research & Therapy 2015 7:53
    Content type: Research Published on:

  40. On 10–11 March 2015 University College London hosted the annual Alzheimer’s Research UK Conference. This report provides an overview of the presentations and discussions that took place.

    Authors: Rosa M. Sancho, Carla J. Cox, Simon H. Ridley, Laura E. Phipps and Eric Karran
    Citation: Alzheimer's Research & Therapy 2015 7:52
    Content type: Meeting report Published on:

  41. Circulating levels of uridine, selenium, vitamins B12, E and C, folate, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been shown to be lower in patients with Alzheimer’s disease (AD) than in hea...

    Authors: Anne Rijpma, Olga Meulenbroek, Anneke M. J. van Hees, John W. C. Sijben, Bruno Vellas, Raj C. Shah, David A. Bennett, Philip Scheltens and Marcel G. M. Olde Rikkert
    Citation: Alzheimer's Research & Therapy 2015 7:51
    Content type: Research Published on:

  42. Because of its genetic underpinnings and consistent age of onset within families, autosomal dominant Alzheimer’s disease (ADAD) provides a unique opportunity to conduct clinical trials of investigational agent...

    Authors: Joshua D. Grill, Randall J. Bateman, Virginia Buckles, Angela Oliver, John C. Morris, Colin L. Masters, William E. Klunk and John M. Ringman
    Citation: Alzheimer's Research & Therapy 2015 7:50
    Content type: Research Published on:

  43. We investigated the association between glucose tolerance status and trajectories of change in blood glucose, and cognitive function in adults aged 25 to 85.

    Authors: Kaarin J. Anstey, Kerry Sargent-Cox, Ranmalee Eramudugolla, Dianna J. Magliano and Jonathan E. Shaw
    Citation: Alzheimer's Research & Therapy 2015 7:48
    Content type: Research Published on:

  44. Emerging evidence for the potential co-contributions of small vessel vasculopathy to dementia has resulted in a more nuanced view of Alzheimer’s disease (AD) pathogenesis. Although cerebral small vessel diseas...

    Authors: Jodi D. Edwards, Joel Ramirez and Sandra E. Black
    Citation: Alzheimer's Research & Therapy 2015 7:49
    Content type: Commentary Published on:

  45. Alzheimer’s disease (AD) is recognized to have a long presymptomatic period, during which there is progressive accumulation of molecular pathology, followed by inexorable neuronal damage. The ability to identi...

    Authors: Philip S.J. Weston, Ivor J.A. Simpson, Natalie S. Ryan, Sebastien Ourselin and Nick C. Fox
    Citation: Alzheimer's Research & Therapy 2015 7:47
    Content type: Review Published on:

  46. Synaptic dysfunction and degeneration are central events in Alzheimer’s disease (AD) pathophysiology that are thought to occur early in disease progression. Synaptic pathology may be studied by examining prote...

    Authors: Hlin Kvartsberg, Erik Portelius, Ulf Andreasson, Gunnar Brinkmalm, Konstantin Hellwig, Natalia Lelental, Johannes Kornhuber, Oskar Hansson, Lennart Minthon, Philipp Spitzer, Juan M Maler, Henrik Zetterberg, Kaj Blennow and Piotr Lewczuk
    Citation: Alzheimer's Research & Therapy 2015 7:40
    Content type: Research Published on:

  47. To facilitate enrollment and meet local registration requirements, sponsors have increasingly implemented multi-national Alzheimer’s disease (AD) studies. Geographic regions vary on many dimensions that may af...

    Authors: David B Henley, Sherie A Dowsett, Yun-Fei Chen, Hong Liu-Seifert, Joshua D Grill, Rachelle S Doody, Paul Aisen, Rema Raman, David S Miller, Ann M Hake and Jeffrey Cummings
    Citation: Alzheimer's Research & Therapy 2015 7:43
    Content type: Research Published on:

  48. Most Alzheimer’s disease (AD) clinical trials enroll participants multinationally. Yet, few data exist to guide investigators and sponsors regarding the types of patients enrolled in these studies and whether ...

    Authors: Joshua D Grill, Rema Raman, Karin Ernstrom, Paul Aisen, Sherie A Dowsett, Yun-Fei Chen, Hong Liu-Seifert, Ann Marie Hake, David S Miller, Rachelle S Doody, David B Henley and Jeffrey L Cummings
    Citation: Alzheimer's Research & Therapy 2015 7:39
    Content type: Research Published on:

  49. Older people with type 2 diabetes are at increased risk of developing cognitive impairment, for which several potential risk factors have been proposed. The present article reviews evidence in people with type...

    Authors: Insa Feinkohl, Jackie F. Price, Mark W.J. Strachan and Brian M. Frier
    Citation: Alzheimer's Research & Therapy 2015 7:46
    Content type: Review Published on:

  50. The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer’s disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed ...

    Authors: Rachelle S Doody, Rema Raman, Reisa A Sperling, Eric Seimers, Gopalan Sethuraman, Richard Mohs, Martin Farlow, Takeshi Iwatsubo, Bruno Vellas, Xiaoying Sun, Karin Ernstrom, Ronald G Thomas and Paul S Aisen
    Citation: Alzheimer's Research & Therapy 2015 7:36
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193